Active Pharmaceutical Ingredients (APIs)

  • Ticagrelor*

    • API Product   :   

      Ticagrelor*

    • CEP   :   

      -

    • WCC   :   

      ?

    • Therapeutic Use    :   

      Blood coagulation system, other products; Antithrombotic agents

    • Originator   :   

      ASTRAZENECA

    • CAS No.    :   

      274693-27-5

    • Trade Name.   :   

      BRILINTA

    • Molecular Weight   :   

      522.567 g/mol

    • Molecular Formula   :   

      C23H28F2N6O4S

    Application

    It may also be used to prevent heart attack or stroke after certain heart surgeries (such as stent placement, coronary artery bypass graft-CABG, or angioplasty). Ticagrelor works by blocking platelets from sticking together and prevents them from forming harmful clots. It is an antiplatelet drug.

    General Description

    Ticagrelor (trade name Brilinta, Brilique, and Possia) is a platelet aggregation inhibitor produced by AstraZeneca. Ticagrelor is an antagonist of the P2Y12 receptor.[1] The drug was approved for use in the European Union by the European Commission on December 3, 2010.[2][3] The drug was approved by the US Food and Drug Administration on July 20, 2011.